Filing Flows › Cytek Biosciences (CTKB) › Q2 2025
Cytek Biosciences (CTKB) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Cytek Biosciences (CTKB) reported revenue of $45.6M for the second quarter 2025 (Q2 2025), -2% from a year earlier and +10% from the quarter before. Operating margin was -23.3%, net loss $5.6M (12.2% of revenue).
Cytek Biosciences, Q2 2025: revenue $45.6M (-2% year over year), operating margin -23.3%, net loss $5.6M, operating cash flow $108K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $45.6M | +10% | -2% |
| Operating profit | −$10.6M | — | — |
| Net earnings | −$5.6M | — | — |
| Operating cash flow | $108K | — | -98% |
What changed
Revenue was $45.6M in Q2 2025, down 2% year over year and up 10% from the previous quarter. Product was the largest line at 69% of revenue. Product lost $3.2M year over year (down 9%), 311% of the total change.
Gross margin was 52.3%, down 2.2 points from a year earlier. Operating costs exceeded revenue by $10.6M, an operating margin of -23.3%. Operating expenses grew 2% against a revenue fall of 2%. The fastest-growing cost line was General & admin (+16%). The quarter ended with a net loss of $5.6M, narrower than the previous quarter's $11.4M loss. Non-operating items added $3.8M, -57% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $108K (down 98% year over year). Non-cash charges added back $1.9M of depreciation and amortization and $6.8M of share-based compensation. Working capital and other items used $3.0M. Capital expenditures of $1.6M exceeded it, leaving free cash flow of −$1.5M.
Questions
What was Cytek Biosciences' revenue in the second quarter 2025?
Cytek Biosciences (CTKB) reported revenue of $45.6M for the second quarter 2025 (Q2 2025), -2% from a year earlier and +10% from the quarter before.
Was Cytek Biosciences profitable in the second quarter 2025?
Operating loss was $10.6M (-23.3% of revenue) and net loss $5.6M.
Source: Cytek Biosciences 10-Q on SEC EDGAR.